Oppenheimer & Co. Inc. Decreases Position in Capricor Therapeutics, Inc. $CAPR

Oppenheimer & Co. Inc. decreased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 16.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,413 shares of the biotechnology company’s stock after selling 27,123 shares during the period. Oppenheimer & Co. Inc. owned about 0.30% of Capricor Therapeutics worth $976,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Legal & General Group Plc grew its stake in Capricor Therapeutics by 8.4% during the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 3,205 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 3,636 shares during the period. Farther Finance Advisors LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth about $28,000. KLP Kapitalforvaltning AS increased its stake in shares of Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after buying an additional 4,300 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 4,976 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CAPR has been the topic of a number of recent analyst reports. HC Wainwright increased their price objective on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Oppenheimer boosted their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Maxim Group raised their price target on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Finally, B. Riley Financial reissued a “buy” rating and set a $50.00 target price (up previously from $21.00) on shares of Capricor Therapeutics in a research report on Monday, December 15th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $22.45 on Monday. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37. The stock has a market cap of $1.03 billion, a PE ratio of -12.47 and a beta of 0.38. The firm has a fifty day moving average price of $25.70 and a 200 day moving average price of $13.78.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.